Lenvatinib: A Review in Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Lenvatinib: A Review in Hepatocellular Carcinoma

Published:2019-04 Issue:6 Volume:79 Page:665-674
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Al-Salama Zaina T.,Syed Yahiya Y.,Scott Lesley J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-019-01116-x.pdf

Reference46 articles.

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.

2. National Comprehensive Cancer Network. Hepatobiliary cancer (NCCN clinical practice guidelines in oncology). 2018. http://www.nccn.org/ . Accessed 26 Mar 2019.

3. European Medicines Agency. Assessment report: lenvima (international non-proprietary name: lenvatinib). 2018. http://www.ema.europa.eu . Accessed 26 Mar 2019.

4. Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.

5. Matsuki M, Hoshi T, Yamamoto Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7(6):2641–53.

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Thieno[2,3-d]pyrimidines as Anticancer VEGFR-2 Inhibitors with Apoptosis Induction: Design, Synthesis, and Biological and In Silico Studies;Medicinal Chemistry;2024-11

2. IL-6/STAT3 signaling pathway induces prostate apoptosis response protein-4(PAR-4) to stimulate malignant behaviors of hepatocellular carcinoma cells;Annals of Hepatology;2024-11

3. Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials;Biomedicine & Pharmacotherapy;2024-10

4. A Bioequivalence Trial of Lenvatinib Mesylate Capsules in Healthy Subjects Under Fasting and Postprandial Conditions;Clinical Pharmacology in Drug Development;2024-09-10

5. GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma;Oncogene;2024-09-09